Quality of life in patients with skeletal metastases of prostate cancer and status prior to start of endocrine therapy: Results from the Scandinavian Prostate Cancer Group study 5

Scandinavian Journal of Urology and Nephrology

Volumn 39, Issue 1, 2005, Pages 42-48

  Jønler, Morten ^a   Nielsen, Ole Steen ^b   Groenvold, Mogens ^c   Hedlund, Per Olov ^d   Damber, Lena ^e   Hedelin, Hans ^f   Waldén, Mauritz ^g  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c BISPEBJERG HOSPITAL   (Denmark)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e UMEÅ UNIVERSITY   (Sweden)

^f Skövde Hospital   (Sweden)

^g Section of Urology   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; OPIATE; POLYESTRADIOL PHOSPHATE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER HORMONE THERAPY; CANCER PAIN; CLINICAL TRIAL; DRUG MEGADOSE; EUROPE; FATIGUE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; SCANDINAVIA; SCORING SYSTEM; SYMPTOMATOLOGY; TRANSURETHRAL RESECTION; TREATMENT OUTCOME;

AGED; BONE NEOPLASMS; ESTRADIOL; ESTROGENS; HEALTH STATUS; HUMANS; MALE; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; REGRESSION ANALYSIS;

EID: 15044339439     PISSN: 00365599     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365590410002528     Document Type: Article

References (13)

1. Green HJ, Pakenham KI, Headley BC, Gardiner RA. Coping and health-related quality of life in men with prostate cancer randomly assigned to hormonal medication or close monitoring. Psychooncology 2002;11:401-14.
2. Adolfsson J. Quality of life. J Urol 2001;166:962-3.
3. Eton DT, Lepore SJ. Prostate cancer and health-related quality of life: a review of the literature. Psychooncology 2002;11:307-26.
4. Hedlund PO, Ala-Opas M, Brekkan E, Damber JE, Damber L, Hagerman I, et al. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer-Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol 2002;36:405-13.
5. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76.
6. Johansson JE, Wersall P, Brandberg Y, Andersson SO, Nordstrom L, EPO-Study Group. Efficacy of epoetin beta on hemoglobin, quality of life, and transfusion needs in patients with anemia due to hormone-refractory prostate cancer-a randomized study. Scand J Urol Nephrol 2001;35:288-94.
7. Hjermstad MJ, Payers PM, Bjordal K, Kaasa S. Health-related quality of life in the general Norwegian population assessed by the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire: the QLQ=C30 (+3). J Clin Oncol 1998;16:1188-96.
8. Michelson H, Bolund C, Nilsson B, Brandberg Y. Health-related quality of life measured by the EORTC QLQ-C30-reference values from a large sample of Swedish population. Acta Oncol 2000;39:477-84.
9. Payers PM. Interpreting quality of life data: population-based reference data for the EORTC QLQ-C30. Eur J Cancer 2001;37:1331-4.
10. Soloway MS. The importance of prognostic factors in advanced prostate cancer. Cancer 1990;66:1017-21.
11. Iversen P. Quality of life issues for patients with prostate cancer. J Urol 2001;166:2291-2.
12. Curran D, Fossa S, Aaronson N, Kiebert G, Keuppens F, Hall R, et al. Baseline quality of life of patients with advanced prostate cancer. European Organization for Research and Treatment of Cancer (EORTC), Genito-Urinary Tract Cancer Cooperative Group (GUT-CCG). Eur J Cancer 1997;33:1809-14.
13. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998;16:139-44.